Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Toxicologic Pathology
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Elangbam, C. S.
Right arrow Articles by Lightfoot, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Elangbam, C. S.
Right arrow Articles by Lightfoot, R. M.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Peroxisome Proliferator-activated Receptors in Atherosclerosis and Inflammation—An Update

Chandikumar S. Elangbam

Department of Pathology, GlaxoWellcome Inc, Research Triangle Park, North Carolina 27709, cse63957{at}GlaxoWellcome.com

Ronald D. Tyler

Department of Toxicology, Medicines Safety Evaluation, GlaxoWellcome Inc, Research Triangle Park, North Carolina 27709

Ruth M. Lightfoot

Department of Toxicology, Medicines Safety Evaluation, GlaxoWellcome Inc, Research Triangle Park, North Carolina 27709

Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor subfamily of transcription factors with pleiotropic effects on intra- and extracellular lipid metabolism, glucose homeostasis, cell proliferation, control of inflammation, and atherosclerosis. Three PPARs, namely {alpha}, {delta}, and {gamma} have been identifi ed with distinct tissue distribution patterns and metabolic functions. PPAR-{alpha} is predominantly expressed in brown adipose tissue, liver, kidney, duodenum, heart, skeletal muscle, and vascular endothelial cells and is involved in the control of lipoprotein metabolism, fatty acid oxidation, and the cellular uptake of fatty acids. PPAR-{gamma} is highly expressed in brown and white adipose tissues and, to lesser extent, in large intestine, retina, and some parts of the immune system, and plays a critical role in adipocyte differentiation and fat deposition. PPAR-{delta} shows a widespread tissue distribution but its regulation and functions are not yet known. Considerable evidence indicates that PPARs (PPAR-{alpha} and PPAR-{gamma} ) have beneficial effects in infl ammatory diseases, including atherosclerosis, through regulation of cytokine production, adhesion molecule expression on the endothelial cells, fi brinolysis, and modulation of monocyte-derived macrophages. In this review, the general and specific roles of the PPAR isotypes and their implications in the control of vascular inflammation and atherosclerosis are discussed.

Key Words: Adipocyte differentiation • atherosclerosis • chemokines • cytokines • inflammation • nuclear receptors • peroxisome proliferator-activated receptors.

Toxicologic Pathology, Vol. 29, No. 2, 224-231 (2001)
DOI: 10.1080/019262301317052495
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Toxicol PatholHome page
C. S. Elangbam, T. A. Brodie, H. Roger Brown, J. B. Nold, T. J. Raczniak, R. D. Tyler, R. M. Lightfoot, and H. G. Wall
Vascular Effects of GI262570X (PPAR-{gamma} agonist) in the Brown Adipose Tissue of Han Wistar Rats: A Review of 1-month, 13-week, 27-week and 2-year Oral Toxicity Studies
Toxicol Pathol, June 1, 2002; 30(4): 420 - 426.
[Abstract] [PDF]